- |||||||||| allopurinol / Generic mfg.
Preclinical, Journal: Xanthine oxidase inhibitory kinetics and mechanism of ellagic acid: In vitro, in silico and in vivo studies. (Pubmed Central) - May 8, 2023
However, there is ongoing debate about the difference in XO inhibitory activity between EA and allopurinol...Furthermore, the authors verified the anti-hyperuricemia effect of EA in vivo. This study elucidates the inhibition kinetics and mechanism of EA on XO, and lays a theoretical foundation for the further development of drugs and functional foods containing EA for the treatment of hyperuricemia.
- |||||||||| itraconazole / Generic mfg., allopurinol / Generic mfg.
Journal: Treatment of Cutaneous Leishmaniasis with Allopurinol Plus Itraconazole in Iran. (Pubmed Central) - May 7, 2023
Recurrence only occurred in one patient in the 3-month follow-up session. This study presents preliminary evidence that oral allopurinol plus itraconazole could be an effective treatment in patients with anthroponotic CL.
- |||||||||| allopurinol / Generic mfg.
Review, Journal: Update in uric acid, hypertension, and cardiovascular diseases. (Pubmed Central) - May 6, 2023
Recently, several prospective randomized controlled intervention trials using allopurinol and other uric acid-lowering drugs have been reported, and the results from these trials were almost negative, suggesting that the correlation between hyperuricemia and cardiovascular disease has no causality...Therefore, we should carry caution in interpreting the results of these studies. This review article presents the results of recent clinical trials using uric acid-lowering drugs, focusing on hypertension and cardiovascular and renal metabolic diseases, and discusses the future of uric acid therapy.
- |||||||||| allopurinol / Generic mfg.
FEBUXIOSTAT AND ALLOPURINOL VERSUS NON-TREATMENT IN HEMODIALYSIS PATIENTS WITH OUTCOMES (Focussed Oral Room 2) - May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1921;
Nevertheless, FEB could not indicate preventive effect for CVD events compared with ALLO and control, which is assumed of ABCG2 inhibitory effect. But was not increase risk for all cause mortality or CVD events compared with ALLO and control.
- |||||||||| allopurinol / Generic mfg.
Trial completion date, Trial primary completion date: Allopurinol to Prevent Cirrhosis Related Morbidities (clinicaltrials.gov) - May 3, 2023
P2/3, N=100, Recruiting,
We identified both combination therapies febuxostat with anakinra or sodium bicarbonate as most beneficial in order to prevent CKD progression in mice. Trial completion date: Oct 2025 --> Aug 2023 | Trial primary completion date: Oct 2025 --> Feb 2023
- |||||||||| allopurinol / Generic mfg.
Preclinical, Journal: Urate-Lowering Therapy Inhibits Thoracic Aortic Aneurysm and Dissection Formation in Mice. (Pubmed Central) - May 2, 2023
Trial completion date: Oct 2025 --> Aug 2023 | Trial primary completion date: Oct 2025 --> Feb 2023 This study uncovered an important and previously unrecognized role of hyperuricemia in mediating the pathogenesis of TAAD, and uric acid-lowering drug may represent a promising therapeutic approach for TAAD.
- |||||||||| allopurinol / Generic mfg.
Journal: Drug adulteration analysis based on complexation with cyclodextrin and metal ions using ion mobility spectrometry. (Pubmed Central) - Apr 27, 2023
Allopurinol (Alp) and theophylline (Thp) are commonly used drugs for the treatment of gout and bronchitis, while their isomers hypoxanthine (Hyt) and theobromine (Thm) have no effect and affect the efficacy of the drug...Finally, the method was applied for the adulteration detection where different drugs and urine were analyzed. In addition, due to the advantages of fast speed, simple operation, high sensitivity, and no chromatographic separation required, the proposed method provides an effective strategy for the drug adulteration detection of isomers.
- |||||||||| Journal: Implementing Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome management system by hospital pharmacists in Samutsakhon Hospital, Thailand. (Pubmed Central) - Apr 24, 2023
The main DRESS management system implementation process is: 1) listing the High alert drugs which may cause an adverse reaction and preparation of pharmacists in DRESS; 2) Using RegiSCAR for patient assessment; 3) Suggesting a genotyping test before the patient receives the drug, starting with carbamazepine and allopurinol; 4) Using a Computerized Decision Support System (CDSS) to facilitate the screening alert...The 4 drug items with the highest incidence were phenytoin 28.95%, nevirapine 10.53%, rifampicin 7.89%, and pyrazinamide 7.89%...In the drug items, the highest incidence was phenytoin. Implementing a system to monitor patients' drug use, could reduce DRESS, and prevent the recurrence of drug allergies.
- |||||||||| allopurinol / Generic mfg.
Review, Journal: Advances in pharmacotherapies for hyperuricemia. (Pubmed Central) - Apr 21, 2023
Differentiating between hyperproducing and hypoexcreting phenotypes may help designing future trials improving the consistency of results. Finally, medications with cardio and nephroprotective properties have shown to reduce serum uric acid levels and may be used in patients with hyperuricemia and other cardiovascular complications.
- |||||||||| cyclophosphamide / Generic mfg.
Trial initiation date: Allo HSCT Using RIC and PTCy for Hematological Diseases (clinicaltrials.gov) - Apr 19, 2023
P2, N=56, Not yet recruiting,
Finally, medications with cardio and nephroprotective properties have shown to reduce serum uric acid levels and may be used in patients with hyperuricemia and other cardiovascular complications. Initiation date: Apr 2023 --> Jul 2023
- |||||||||| Enrollment closed, Trial primary completion date: Allo HSCT Using RIC for Hematological Diseases (clinicaltrials.gov) - Apr 19, 2023
P2, N=156, Active, not recruiting,
Initiation date: Apr 2023 --> Jul 2023 Suspended --> Active, not recruiting | Trial primary completion date: Mar 2024 --> Apr 2023
- |||||||||| Trial completion date, Trial primary completion date: Allo HSCT Using RIC for Hematological Diseases (clinicaltrials.gov) - Apr 18, 2023
P2, N=124, Suspended,
(2) Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
- |||||||||| allopurinol / Generic mfg.
Enrollment open, Trial initiation date: Allopurinol to Prevent Cirrhosis Related Morbidities (clinicaltrials.gov) - Apr 18, 2023
P2/3, N=100, Recruiting,
Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024 Not yet recruiting --> Recruiting | Initiation date: Oct 2022 --> Jun 2022
- |||||||||| allopurinol / Generic mfg.
Journal: Allopurinol hypersensitivity syndrome. (Pubmed Central) - Apr 4, 2023
Not yet recruiting --> Recruiting | Initiation date: Oct 2022 --> Jun 2022 No abstract available
- |||||||||| allopurinol / Generic mfg.
Causal Effect Estimation of Follow-up 24-Hour Urine Testing on Adherence to Preventive Pharmacologic Therapy (S405) - Mar 30, 2023 - Abstract #AUA2023AUA_1554;
Using claims data from working-age, commercially insured adults with USD (2008 to 2019), we identified those prescribed PPT (a thiazide diuretic, alkali citrate therapy, or allopurinol) after receiving a baseline 24-hour urine test in the 180 days prior to the initial PPT fill... Obtaining a follow-up 24-hour urine test after initiating PPT had a statistically significant spillover causal effect to improve patient adherence to PPT.
- |||||||||| allopurinol / Generic mfg.
Preclinical, Journal: Notopterol Ameliorates Hyperuricemia-Induced Cardiac Dysfunction in Mice. (Pubmed Central) - Mar 30, 2023
Notopterol (20 mg/kg) and allopurinol (10 mg/kg) were given daily as treatment, respectively...Notopterol inhibited pyroptosis via inhibiting the P2X7R/NLRP3 signaling pathway under uric acid stimulation. Notopterol might represent a potential therapeutic strategy against pyroptosis and improve cardiac function in hyperuricemic mice.
- |||||||||| allopurinol / Generic mfg.
FAMILIAL HYPERURICEMIC INTERSTITIAL NEPHRITIS, A CHALLENGE FOR ETIOLOGIC DIAGNOSIS () - Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_902;
Among affected patients, median age at diagnosis was 29.5yo (IQR 18.25-41.25), serum creatinine 1.37mg/dL (IQR 0.83-2.40), urinary protein to creatinine ratio of 0.084mg/g (IQR 0.084-0.171) and serum uric acid 4.8 (IQR 3.40-6.0) all under allopurinol treatment...This pathogenic variant, alters both the structure and function of mitochondrial tRNAPhe, leadind to impaired mitochondrial translation and mitochondrial respiratory deficiency.This mutation has already been described in a few families that presented either isolated tubulointerstitial kidney disease, with or without hyperuricemia, or a predominant neurological involvement, with history of epilepsy. Further studies including this genetic variant should be performed in order to establish its pathogenic role in patients with hyperuricaemic MiTKD.
- |||||||||| Darier-Roussy Sarcoid (Walter E. Washington Convention Center, Area E, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_8188;
Early diagnosis is important for the treatment and prevention of progression to systemic disease. More study needs to be conducted to know the etiology and treatment options available to minimize the chance of recurrence.
- |||||||||| Friday Leukemia? When a Patient With Acute Myelocytic Leukemia Present With Pneumonia on a Friday (Walter E. Washington Convention Center, Area B, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_6848;
However, a year later, the patient remitted and was started on Ventoclax + Azacitidine which he had received two weeks prior...Hydroxyurea and allopurinol were given for empiric management of pulmonary leukostasis since the patient was unfit to receive induction chemotherapy...As in our case, pulmonary leukostasis can contribute to a patient's respiratory distress. Therefore, a high degree of suspicion is required to arrive at a diagnosis.
- |||||||||| Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Hiding in Plain Hindsight: A Case of Cardiac Amyloidosis (Walter E. Washington Convention Center, Area C, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_5069;
It consists of daratumumab, cyclophosphamide, bortezomib and dexamethasone...His disease course was complicated by tumor lysis syndrome, despite allopurinol prophylaxis, as well as an intensive care unit admission requiring renal replacement therapy and vasopressor support...It is normally seen in males in the 5th decade of life. As a result, it is important to keep cardiac amyloidosis as a differential diagnosis when evaluating a patient with heart failure symptoms who continue to have uncontrolled symptoms, so diagnosis and treatment are not delayed.
- |||||||||| piperacillin sodium/tazobactam sodium / Generic mfg., foscarnet / Generic mfg., allopurinol / Generic mfg.
A Rare and Unfortunate Case of Steven Johnson Syndrome (SJS) Potentiated by Cytomegalovirus (CMV) Reactivation (Walter E. Washington Convention Center, Room 206 (Level 2)) - Mar 25, 2023 - Abstract #ATS2023ATS_3002;
They can be triggered by various agents and the precise underlying mechanism remains elusive to date.CASE PRESENTATION40-year-old male with history of alcohol use disorder, liver cirrhosis and recent admission one week ago for pneumonia & latent syphilis (treated with piperacillin-tazobactam & penicillin respectively) presented to the hospital with pneumonia, rash and altered mentation...Treatment for CMV with foscarnet was started but the patient developed DIC, acute renal failure requiring intubation and pressor support...reported an incidence of 9.2 per million adults per year in the US from 2009-2012 for SJS with 4.8-9% mortality.2 Triggers such as drugs (including antiepileptics, antibiotics, NSAIDs, immune checkpoint inhibitors, Allopurinol etc.), infections (Mycoplasma pneumoniae, HIV), malignancies etc., have been implicated as causative agents...Induction and maintenance of a potent memory T cell response by herpesviruses has been implicated as the possible underlying mechanism.4 Similar cases described before include Cruz M et al., SJS associated with CMV infection in a child with ependymoma; Tagajdid MR et al., Reactivation of CMV in a patient with SJS-TEN; and Khalaf D et al., TEN associated with severe CMV infection in a patient on regular hemodialysis. Our case adds to this scarce database of CMV potentiated SJS and serves as a reminder that if not promptly treated, SJS can be life-threatening.IMAGE-1- Erythematous rash and Skin erosions on patient's back.
|
